New Perspectives on Canine Splenic Hemangiosarcoma
This lecture has been RACE Approved for 1 CE hour for veterinarians and veterinary technicians.
Canine splenic hemangiosarcoma is recognized as one of the most aggressive cancers in the veterinary field. New and ongoing research seeks to change this and deliver curative outcomes to patients. Much of this new research has emerged from a new genomic understanding of the cancer and the opportunity to study new approaches to treatment. Specifically, a nation-wide prospective clinical trial of 400 dogs with splenic tumor rupture and hemoabdomen is open and seeks curs for this disease. This new clinical trial (Ethos PUSH) and the values it offers clients and the field will be discussed and summarized.